Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 9:34 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,690 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Men Clear all
Withdrawn Phase 3 Interventional

Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer

NCT04225299
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
TOOKAD®
Drug
Lead sponsor
Steba Biotech S.A.
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Nov 1, 2026, 9:34 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Cardiometabolic Health in Transgender Males

NCT04977765
View directory record Official record
Conditions
Transgender, Transgenderism
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
12 Years to 30 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 3 Interventional

Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer

NCT02615067
View directory record Official record
Conditions
Prostate Cancer
Interventions
99mTc-MIP-1404 Injection, Whole-Body Planar and pelvic SPECT/CT scan
Drug · Diagnostic Test
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Nov 1, 2026, 9:34 AM EST
Completed No phase listed Observational Accepts healthy volunteers Results available

Peak Impact Forces and Metabolic Cost During Mid-Forefoot Striking in Shod Versus Barefoot Runners

NCT01536171
View directory record Official record
Conditions
Healthy
Interventions
running with normal running shoes and barefoot
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 4 Interventional Results available

A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants

NCT04320745
View directory record Official record
Conditions
Hypogonadism
Interventions
Androderm®
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 2 Interventional Results available

Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

NCT00936975
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions
Fluorine F 18 Sodium Fluoride
Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts • Durham, North Carolina • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Nov 1, 2026, 9:34 AM EST
Active, not recruiting Phase 2 Interventional

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

NCT03950609
View directory record Official record
Conditions
Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1, Neuroendocrine Neoplasm, Unresectable Carcinoid Tumor
Interventions
Everolimus, Lenvatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 1, 2026, 9:34 AM EST
Enrolling by invitation Not applicable Interventional

Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia

NCT07637071
View directory record Official record
Conditions
Androgenic Alopecia, Hair Loss/Baldness, Hair Thinning
Interventions
Xtressé Hair Growth Gummies, Placebo Comparator
Other · Dietary Supplement
Lead sponsor
Restore Biologics Holdings, Inc. dba Xtressé
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Maitland, Florida • Port Orange, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 2 Interventional Results available

Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV

NCT00949234
View directory record Official record
Conditions
HIV Prevention, HIV Infections
Interventions
tenofovir + emtricitabine, lopinavir/ritonavir
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2017 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men

NCT01382069
View directory record Official record
Conditions
Healthy Men, Male Contraception
Interventions
Dimethandrolone Undecanoate, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 1 Interventional Results available

Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men

NCT01104246
View directory record Official record
Conditions
Hypogonadism
Interventions
Testerone Transdermal System
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Miramar, Florida • Omaha, Nebraska • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Nov 1, 2026, 9:34 AM EST
Completed Not applicable Interventional Results available

Penile Length Restoration in Men With Diabetes Mellitus, Type II

NCT03756688
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Penile Diseases
Interventions
RestoreX PTT - 6 months, RestoreX PTT - 3 months
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Nov 1, 2026, 9:34 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Rapid HIV Self-testing Among MSM (eSTAMP)

NCT02067039
View directory record Official record
Conditions
HIV Infection
Interventions
OraQuick in home & Sure Check HIV tests
Device
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older · Male only
Enrollment
2,665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 2 Interventional Results available

Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia

NCT00940901
View directory record Official record
Conditions
Sickle Cell Disease, Priapism
Interventions
sildenafil, placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years to 45 Years · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 3 Interventional Results available

Testosterone Administration and ACL Reconstruction in Men

NCT01595581
View directory record Official record
Conditions
Muscle Atrophy, ACL Reconstruction, Trauma, Osteoarthritis
Interventions
Testosterone, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

NCT02312557
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma Cancer AJCC v8
Interventions
Enzalutamide, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin

NCT01686828
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
Interventions
Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole)
Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 3 Interventional Results available

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

NCT01532414
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Mobile, Alabama • Little Rock, Arkansas • Garden Grove, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 2 Interventional Results available

Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

NCT00386009
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
8
States / cities
Newport Beach, California • Tarzana, California • Middlebury, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2009 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 2 Interventional Results available

Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139

NCT02362464
View directory record Official record
Conditions
Prostatic Neoplasms, Neoplasms of Prostate, Prostate Cancer, Cancer Of Prostate, Stage D0 Prostate Cancer
Interventions
Multi-epitope (ME) T-cell Receptor Alternate Reading Frame Protein (TARP) vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 2 Interventional

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

NCT02130700
View directory record Official record
Conditions
Prostate Cancer
Interventions
VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles
Drug
Lead sponsor
Innocrin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Nov 1, 2026, 9:34 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Oral Supplementation With a Black Pepper Extract

NCT05199012
View directory record Official record
Conditions
Waist Circumference, Triglycerides, Appetite, Inflammation, Lipids
Interventions
Black pepper extract
Dietary Supplement
Lead sponsor
The Center for Applied Health Sciences, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Canfield, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Nov 1, 2026, 9:34 AM EST
Completed Phase 4 Interventional Results available

Effect of Probiotic Supplementation on Endothelial Function

NCT01952834
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
GoodBelly Probiotic, Vancomycin
Dietary Supplement · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
40 Years to 75 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Milwauke, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Nov 1, 2026, 9:34 AM EST
Withdrawn Early Phase 1 Interventional

Daily, Long-Term Intermittent Fasting for the Prevention of PSA-Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy

NCT04288336
View directory record Official record
Conditions
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Food Diary, Preventative Dietary Intervention, Questionnaire Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Nov 1, 2026, 9:34 AM EST